Alfons A. Den Broeder

Ubbergen, GE, Netherlands

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 189 publications

Low value of routine serological screening for hepatitis B in patients with rheumatoid arthritis starting rituximab therapy in a nonendemic region.

Low value of routine serological screening for hepatitis B in patients with rheumatoid arthritis starting rituximab therapy in a nonendemic region.

Journal: EULAR rheumatology open

Published: June 29, 2026

Early progression of systemic sclerosis: a longitudinal cohort study on disease evolution and microvascular changes.

Early progression of systemic sclerosis: a longitudinal cohort study on disease evolution and microvascular changes.

Journal: EULAR rheumatology open

Published: June 29, 2026

Polymyalgia Rheumatica.

Polymyalgia Rheumatica.

Journal: The New England journal of medicine

Published: June 03, 2026

Subcutaneous versus intravenous ultra-low dose rituximab in rheumatoid arthritis: a randomised controlled PK-PD non-inferiority trial.

Subcutaneous versus intravenous ultra-low dose rituximab in rheumatoid arthritis: a randomised controlled PK-PD non-inferiority trial.

Journal: Rheumatology (Oxford, England)

Published: February 03, 2026

Oral glucocorticoid premedication for preventing infusion-related reactions to rituximab in rheumatoid arthritis.

Oral glucocorticoid premedication for preventing infusion-related reactions to rituximab in rheumatoid arthritis.

Journal: Scandinavian journal of rheumatology

Published: January 23, 2026

Measurement properties of the Polymyalgia Rheumatica Activity Score (PMR-AS): reliability, measurement error and discriminative validity.

Measurement properties of the Polymyalgia Rheumatica Activity Score (PMR-AS): reliability, measurement error and discriminative validity.

Journal: Rheumatology (Oxford, England)

Published: November 28, 2025

Long-Term Routine Laboratory Toxicity Monitoring of Immunomodulatory Drugs in Rheumatoid Arthritis : A Retrospective Cohort Study.

Long-Term Routine Laboratory Toxicity Monitoring of Immunomodulatory Drugs in Rheumatoid Arthritis : A Retrospective Cohort Study.

Journal: Annals of internal medicine

Published: August 25, 2025

Similar gout flare incidence rates when using once- or twice-daily 0.5 mg colchicine prophylaxis after the start of xanthine oxidase inhibitors.

Similar gout flare incidence rates when using once- or twice-daily 0.5 mg colchicine prophylaxis after the start of xanthine oxidase inhibitors.

Journal: Scandinavian journal of rheumatology

Published: August 11, 2025

Results of a 1-year randomised double-blind placebo-controlled trial with methotrexate 25 mg/week in recently diagnosed polymyalgia rheumatica.

Results of a 1-year randomised double-blind placebo-controlled trial with methotrexate 25 mg/week in recently diagnosed polymyalgia rheumatica.

Journal: Annals of the rheumatic diseases

Published: July 22, 2025

Disease Activity Score in 28 joints using C-reactive protein based remission state and still residual swollen joints: theoretically possible, but does it occur in the real world?

Disease Activity Score in 28 joints using C-reactive protein based remission state and still residual swollen joints: theoretically possible, but does it occur in the real world?

Journal: Scandinavian journal of rheumatology

Published: July 07, 2025

Identification of new overlapping and disease-specific genetic risk factors for rheumatoid arthritis and radiographic axial spondyloarthritis: a meta-analysis of three large European populations and functional characterization.

Identification of new overlapping and disease-specific genetic risk factors for rheumatoid arthritis and radiographic axial spondyloarthritis: a meta-analysis of three large European populations and functional characterization.

Journal: Frontiers in immunology

Published: May 29, 2025

Cohort Study on Drug Survival and Tolerability of Adalimumab Biosimilar Transitioning: Pharmaceutical Properties Do Matter.

Cohort Study on Drug Survival and Tolerability of Adalimumab Biosimilar Transitioning: Pharmaceutical Properties Do Matter.

Journal: Clinical pharmacology and therapeutics

Published: May 09, 2025

Showing 1-12 of 189

Last Updated: 09/26/2026